Payment overview · 2025
General Payments
$1,608.60
89 reported records · 15 companies
Healthcare provider profile · identity verified
Renee Ellen Walter, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MYRTLE BEACH, SC · NPI 1245948041
Verified facts
What the public records show
CMS Open Payments records show Renee Ellen Walter, APN received $1,608.60 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $425.01 | 26.4% | 38 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $295.47 | 18.4% | 11 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $222.32 | 13.8% | 8 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $148.08 | 9.2% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $130.30 | 8.1% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $81.13 | 5.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.44 | 4.2% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.03 | 3.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.70 | 3.5% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.09 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.45 | 1.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.59 | 1.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.70 | 1.2% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $16.72 | 1.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $13.57 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,608.60 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $425.01 | 38 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $246.05 | 8 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $222.32 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $130.30 | 6 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $128.27 | 6 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $101.17 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $81.13 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $67.44 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $60.03 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.70 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 98 |
| Omeprazole | Omeprazole | 218 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 74 |
| Alprazolam | Alprazolam | 203 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 70 |
| Lisinopril | Lisinopril | 193 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 71 |
| Losartan Potassium | Losartan Potassium | 172 | 57 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 154 | 68 |
| Gabapentin | Gabapentin | 131 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 42 |
| Simvastatin | Simvastatin | 121 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 49 |
| Famotidine | Famotidine | 112 | 40 |
| Furosemide | Furosemide | 111 | 40 |
| Metformin Hcl | Metformin Hcl | 108 | 41 |
| Sertraline Hcl | Sertraline Hcl | 94 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 28 |
| Trazodone Hcl | Trazodone Hcl | 86 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Atenolol | Atenolol | 70 | 27 |
| Ozempic | Semaglutide | 68 | 14 |
| Meloxicam | Meloxicam | 67 | 28 |
| Eliquis | Apixaban | 61 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 47 |
| Ezetimibe | Ezetimibe | 57 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 16 |
| Nifedipine Er | Nifedipine | 50 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 15 |
| Temazepam | Temazepam | 49 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 18 |
| Montelukast Sodium | Montelukast Sodium | 46 | 17 |
| Celecoxib | Celecoxib | 45 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 28 |
| Allopurinol | Allopurinol | 43 | 16 |
| Metformin Hcl Er | Metformin Hcl | 42 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 15 |
| Spironolactone | Spironolactone | 38 | 17 |
| Carvedilol | Carvedilol | 35 | 15 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 17 |
| Meclizine Hcl | Meclizine Hcl | 33 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Valsartan | Valsartan | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Ibuprofen | Ibuprofen | 17 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,608.60 · 89 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, Dyanavel XR, INGREZZA, Jornay PM, LYBALVI, Qelbree, REXULTI, SPRAVATO, SUBLOCADE, TRINTELLIX, VIVITROL, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error